Browse ERAP2

Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type II membrane protein
Domain PF11838 ERAP1-like C-terminal domain
PF01433 Peptidase family M1
Function

Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Preferentially hydrolyzes the basic residues Arg and Lys.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002483 antigen processing and presentation of endogenous peptide antigen
GO:0003013 circulatory system process
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0019882 antigen processing and presentation
GO:0019883 antigen processing and presentation of endogenous antigen
GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I
GO:0043171 peptide catabolic process
GO:0048002 antigen processing and presentation of peptide antigen
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004175 endopeptidase activity
GO:0004177 aminopeptidase activity
GO:0008235 metalloexopeptidase activity
GO:0008237 metallopeptidase activity
GO:0008238 exopeptidase activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0070006 metalloaminopeptidase activity
Cellular Component GO:0005788 endoplasmic reticulum lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983170: Antigen Presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ERAP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ERAP2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21252114LymphomaPromote immunityThe endoplasmic reticulum aminopeptidase ERAAP is involved in the final trimming of peptides for presentation by MHC class I (MHC-I) molecules. Herein, we show that ERAAP silencing results in MHC-I peptide-loading defects eliciting rejection of the murine T-cell lymphoma RMA in syngeneic mice. Because a large fraction of human tumors express high levels of the homologous ERAP1 and/or ERAP2, the present findings highlight a convenient, novel target for cancer immunotherapy.
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ERAP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ERAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.210.768
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1490.936
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2210.832
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4460.194
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.530.775
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3530.863
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8140.21
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7980.607
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7680.669
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3930.799
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.040.986
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0170.926
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ERAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERAP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERAP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERAP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERAP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ERAP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ERAP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolERAP2
Nameendoplasmic reticulum aminopeptidase 2
Aliases L-RAP; LRAP; leukocyte-derived arginine aminopeptidase
Chromosomal Location5q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ERAP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.